secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001213900-24-076111
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology's LYMPHIR added to NCCN Guidelines (Category 2A) for CTCL
-------------------------------------------------------------------------

- LYMPHIR (denileukin diftitox-cxdl) included in NCCN Guidelines for relapsed/refractory Cutaneous T-cell Lymphoma as Category 2A recommendation.
- FDA-approved therapy targets IL-2 receptor on malignant T-cells; Phase 3 Study 302 supported approval.
- CEO Mazur states inclusion may aid adoption and ease reimbursement, especially for CMS coverage.
- NCCN Guidelines are widely used for clinical decision-making and payer reimbursement in the U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024076111/0001213900-24-076111-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390024076111/ea0213635-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-076111

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer